GlassScriptPhysician profile
Muthu S Krishnan
NPI 1528089539
$19,934.37
in general payments reported to CMS, 2019-2025
37 companies · $2,642 in 2025
The $2,642 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,601 · 2020: $1,786 · 2021: $2,243 · 2022: $2,984 · 2023: $2,209 · 2024: $6,470 · 2025: $2,642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $6,136 · Food and Beverage: $5,164 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $6,135.93 |
| Food and Beverage | $5,164.34 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $10,701.18 | 2019-2025 | Aveir, Xact, Optis |
| Boston Scientific Corporation | $1,389.51 | 2019-2025 | Rotapro, Watchman Access System, Flextome Cutting Balloon |
| Janssen Pharmaceuticals, INC | $1,280.35 | 2019-2024 | Xarelto |
| Medtronic, INC. | $927.97 | 2022-2025 | Symplicity G3, Onyx Frontier, Hawkone |
| Novartis Pharmaceuticals Corporation | $795.35 | 2019-2025 | |
| Amgen INC. | $478.47 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $476.20 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $456.32 | 2019-2024 | Farxiga, Brilinta |
| Pfizer INC. | $449.43 | 2019-2025 | |
| Amarin Pharma, INC. | $386.51 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $367.36 | 2019-2024 | Lifevest |
| Abiomed | $355.44 | 2019-2025 | Impella |
| Merck Sharp & Dohme LLC | $354.35 | 2021-2025 | Verquvo, Capvaxive |
| Vifor Pharma, INC. | $200.00 | 2021 | |
| Edwards Lifesciences Corporation | $195.23 | 2021-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endologix LLC | $121.51 | 2025 | Endocross Device, Torus Stent Graft System |
| Shockwave Medical, INC | $108.99 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Philips North America LLC | $108.87 | 2022-2025 | Event, (Ck4) Mcot, Holter |
| Acist Medical Systems, INC. | $102.34 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.70 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $90.58 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $88.92 | 2023-2024 | Inpefa |
| Zoll Circulation INC | $54.24 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $50.45 | 2019 | |
| Irhythm Technologies, INC. | $36.89 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Biotronik INC. | $36.67 | 2019-2021 | |
| Getinge USA Sales, LLC | $33.64 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $25.00 | 2025 | Amvuttra |
| Sanofi-Aventis U.S. LLC | $24.73 | 2020-2022 | |
| Cvrx, INC. | $23.92 | 2024 | Barostim Neo System |
| Kestra Medical Technology Services, INC. | $21.38 | 2025 | Assure Wcd |
| Kiniksa Pharmaceuticals, LTD. | $20.77 | 2023 | Arcalyst |
| Cook Medical LLC | $19.78 | 2019 | |
| Novo Nordisk INC | $16.77 | 2025 | Wegovy |
| Chiesi USA, INC. | $13.88 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $13.67 | 2019 | |
| Bardy Diagnostics, INC. | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muthu Krishnan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.